fda safety communication semaglutide vision loss naion 2025 & Loss: What the Latest Research Says 👁️💉 A new multinational study analyzing health records from over 290,000 patients found no significant link between Semaglutide use and the risk of GLP-1 Vision Loss Lawsuit: An

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have garnered significant attention for their dual effects in glucose control and weight reduction.

Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, announced it will expand its

GLP-1 patches are popping up everywhere online, promising needle-free weight loss support and an easy alternative to injections

Natalie Muth), posted on Mar 13, 2026.

Additionally, this electrolyte powder offers a very unique blend of calcium, magnesium, and trace mineral complex

These findings support the utility of GLP-1 agonists for managing cardiometabolic risk in schizophrenia and may inform future guideline updates for long-term health outcomes